ICU Medical price target raised to $147 from $136 at KeyBanc

KeyBanc raised the firm’s price target on ICU Medical to $147 from $136 and keeps an Overweight rating on the shares post Q2 on higher multiple/estimates. While there are still a few considerations for the second half of 2024, the firm was “broadly encouraged” by the magnitude of Q2 outperformance and it is tracking ahead of previous expectations.